erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

Journal of the National Cancer Institute

Volumn 90, Issue 18, 1998, Pages 1346-1360

  Thor, Ann D ^a,k   Berry, Donald A ^b   Budman, Daniel R ^c   Muss, Hyman B ^d   Kute, Timothy ^e   Henderson, I Craig ^f   Barcos, Maurice ^g   Cirrincione, Constance ^b   Edgerton, Susan ^a   Allred, Craig ^h   Norton, Larry ⁱ   Liu, Edison T ^j,l  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Cancer Leukemia Grp B Stat Ctr   (United States)

^c NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

^h UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j UNIVERSITY OF NORTH CAROLINA   (United States)

^k EVANSTON HOSPITAL   (United States)

^l NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; ONCOPROTEIN; PROTEIN P53;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; ONCOGENE NEU; POLYMERASE CHAIN REACTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 0032538050     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.18.1346     Document Type: Article

References (34)

1. Goldhirsch A, Gelber RD. Understanding adjuvant chemotherapy for breast cancer [editorial]. N Engl J Med 1994;330:1308-9.
2. Bonadonna G. Karnofsky Memorial Lecture. Conceptual and practical advances in the management of breast cancer. J Clin Oncol 1989;7: 1380-97.
3. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,000 women. N Engl J Med 1988;319:1681-92.
4. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1-15, 71-85.
5. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, et al. Dose and dose intensity of adjuvant chemotherapy for stage II. node-positive breast carcinoma [published erratum appears in N Engl J Med 1994;331:139]. N Engl J Med 1994;330:1253-9.
6. Recht A, Come SE, Henderson IC, Gelman RS, Silver B, Haves DF, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996;334: 1356-61.
7. National Institutes of Health Consensus Development Panel. Consensus statement: treatment of early-stage breast cancer. J Natl Cancer Inst Monogr 1992;11:1-5.
8. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992;10:1049-56.
9. Stal O, Sullivan S, Wingren S, Skoog L, Rutqvist LE, Carstensen JM, et al. c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 1995;31A:2185-90.
10. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-6.
11. Clark GM. Prognostic and predictive factors. In: Harris JR, Lippman ME, Morrow M, Hellman S, editors. Diseases of the breast. Philadelphia: Lippincott-Raven; 1996. p. 461-85.
12. Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, et al. Dose and dose intensity are determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 1998;90:issue No. 16.
13. Black MM, Opler SR, Speer FD. Survival in breast cancer cases in relation to the structure of the primary tumor and regional lymph nodes. Surg Gynecol Obstet 1955;100:543-51.
14. Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihsaus ES, Lynch HT, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992; 84:845-55.
15. Kupryjanczyk J, Thor AD, Beauchamp R, Merritt V, Edgerton SM, Bell DA, et al. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci U S A 1993;90: 4961-5.
16. Liu E, Thor A, He M, Barcos M, Ljung BM, Benz C. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 1992;7:1027-32.
17. Neubauer A, Neubauer B, He M, Effert P, Iglehart D, Frye RA, et al. Analysis of gene amplification in archival tissue by differential polymerase chain reaction. Oncogene 1992;7:1019-25.
18. Jacobs TW, Prioleau JE, Stillman IE, Schnitt SJ. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 1996;88: 1054-9.
19. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of situ to invasive breast cancer. Hum Pathol 1992;23:974-9.
20. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV,. et al. Design and analysis of randomized clinical trails requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976;34: 585-612.
21. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Desisn and analysis of randomized trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35: 1-39.
22. Zar JH, Biostatistical analysis. Englewood Cliffs (NJ): Prentice-Hall: 1974.
23. Cox DR. Regression models and life tables (with discussion). J Royal Stat Soc 1972;34:187-220.
24. Berry DA, Thor A, Cirrincione C, Edgerton S, Muss H, Marks J, et al. Scientific inference and predictions: multiplicities and convincing stories: a case study in breast cancer therapy. In: Bernardo JM, Berger JO, Dawid AP, Smith AF, editnrs. Baysian statistics 5. Oxford: Oxford University Press: 1996. p. 45-67.
25. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54: 2771-7.
26. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
27. Ravdin PM, Chamness GC. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers - a review. Gene 1995;159:19-27.
28. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992;10:599-605.
29. Perloff M, Norton L, Korzun AH, Wood WC, Carey RW, Gottlieb A, et al. Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study. J Clin Oncol 1996;14:1589-98.
30. Saffari B, Jones LA, el-Naggar A, Felix JC, George J, Press MF. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival. Cancer Res 1995;55:5693-8.
31. Berry DA. When is a confirmatory randomized clinical trial needed? [editorial]. J Natl Cancer Inst 1996;88:1606-7
32. Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996;381:713-6.
33. Lowe S, Jacks T. p53 and treatment of bladder cancer. Nature 1997;385: 123-4.
34. Bitran JD, Samuels B, Trujillo Y, Klein L, Schroeder L, Martinee J. Her2/ neu overexpression is associated with treatment failure in women with high-risk stage II and IIIA breast cancer treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy. Clin Cancer Res 1996;2: 1509-13.